Healthcare Industry News: Amicus Therapeutics
News Release - October 2, 2006
Amicus Therapeutics Appoints Chief Financial OfficerCRANBURY, N.J., Oct. 2 (HSMN NewsFeed) -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of James E. Dentzer as Chief Financial Officer (CFO). Mr. Dentzer joins Amicus from Biogen Idec Inc., where he served as Vice President and Corporate Controller.
"Jim has outstanding experience in the pharmaceutical and consumer products industries," stated Donald J. Hayden, Jr., Executive Chairman and Interim President and CEO of Amicus. "He is a great addition to what is already an excellent management team at Amicus and I know he will contribute significantly to the continued growth and success of the company."
Prior to joining Biogen Idec, Mr. Dentzer served in a variety of financial positions at E. I. du Pont de Nemours and Company, including serving as Chief Financial Officer of DuPont Flooring Systems. Mr. Dentzer also held various positions at Kemper Financial Services and at Bank of Boston. Mr. Dentzer received a B.A. from Boston College and an M.B.A. from the University of Chicago.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded proteins caused by genetic mutations. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase II clinical trials for its lead compound, Amigal(TM), for Fabry disease, and is conducting Phase I clinical trials of AT2101 for Gaucher disease. The company also plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.
Source: Amicus Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.